Danaher Corporation (DHR)vsGRAIL, LLC (GRAL)
DHR
Danaher Corporation
$187.15
-1.55%
HEALTHCARE · Cap: $134.43B
GRAL
GRAIL, LLC
$52.29
+7.48%
HEALTHCARE · Cap: $2.00B
Smart Verdict
WallStSmart Research — data-driven comparison
Danaher Corporation generates 16593% more annual revenue ($24.57B vs $147.17M). DHR leads profitability with a 14.7% profit margin vs -2.8%. DHR earns a higher WallStSmart Score of 60/100 (C).
DHR
Buy60
out of 100
Grade: C
GRAL
Avoid34
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-38.6%
Fair Value
$135.07
Current Price
$187.15
$52.08 premium
Intrinsic value data unavailable for GRAL.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Reasonable price relative to book value
Strong operational efficiency at 22.2%
Generating 1.7B in free cash flow
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
4.6% revenue growth
ROE of 7.0% — below average capital efficiency
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -16.1% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : DHR
The strongest argument for DHR centers on Market Cap, Price/Book, Operating Margin. PEG of 1.23 suggests the stock is reasonably priced for its growth.
Bull Case : GRAL
The strongest argument for GRAL centers on Price/Book. Revenue growth of 14.0% demonstrates continued momentum.
Bear Case : DHR
The primary concerns for DHR are P/E Ratio, Revenue Growth, Return on Equity.
Bear Case : GRAL
The primary concerns for GRAL are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
DHR profiles as a value stock while GRAL is a turnaround play — different risk/reward profiles.
GRAL is growing revenue faster at 14.0% — sustainability is the question.
DHR generates stronger free cash flow (1.7B), providing more financial flexibility.
Monitor DIAGNOSTICS & RESEARCH industry trends, competitive dynamics, and regulatory changes.
Bottom Line
DHR scores higher overall (60/100 vs 34/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Danaher Corporation
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Danaher Corporation is an American globally diversified conglomerate with its headquarters in Washington, D.C.. The company designs, manufactures, and markets professional, medical, industrial, and commercial products and services. The company's 3 platforms are Life Sciences, Diagnostics, and Environmental & Applied Solutions.
GRAIL, LLC
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
GRAIL, LLC is a pioneering biotechnology firm focused on revolutionizing cancer detection through its state-of-the-art blood tests designed for early diagnosis. With its proprietary genomic technologies, GRAIL is at the forefront of the multi-cancer early detection (MCED) market, empowering individuals with essential information for proactive healthcare management. The company's dedication to advancing precision medicine not only aims to improve patient outcomes but also addresses critical gaps in cancer screening and diagnostics, positioning GRAIL as a crucial player in the future landscape of oncology.
Visit Website →Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?